Covid-19 roundup: New study sug­gests Mod­er­na vac­cine may be more ef­fec­tive than Pfiz­er against the Delta vari­ant; Pen­ta­gon to re­quire vac­cines for mem­bers of the mil­i­tary 

A study of pa­tients in the Mayo Clin­ic Health Sys­tem across mul­ti­ple states sug­gests those who re­ceived Pfiz­er’s Covid-19 vac­cine are at a two-fold high­er risk of break­through in­fec­tion com­pared to those who got the Mod­er­na vac­cine.

It’s im­por­tant to note that the study, pub­lished Sun­day in the preprint serv­er medRx­iv, has not been peer-re­viewed.

The study be­gan in Min­neso­ta, where re­searchers have been an­a­lyz­ing the ef­fi­ca­cy of the vac­cines on a month­ly ba­sis since Feb­ru­ary 2021. As cas­es in­creased in Ju­ly and the Delta vari­ant be­came more promi­nent, the sci­en­tists mea­sured a 76% ef­fi­ca­cy against in­fec­tion for the Mod­er­na vac­cine, and a 42% ef­fi­ca­cy against in­fec­tion for Pfiz­er’s. Those rates are much low­er than the fig­ures seen through April 2021 (93.3% for Mod­er­na and 86.1% for Pfiz­er).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.